How Often Should We Eat

This study is currently recruiting participants.
Verified May 2012 by Rigshospitalet, Denmark
Sponsor:
Information provided by (Responsible Party):
Inge Holm, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier:
NCT01378208
First received: June 15, 2011
Last updated: May 31, 2012
Last verified: May 2012
  Purpose

The Danish Food Administration recommends eating three main meals and three small meals a day in order to maintain a healthy lifestyle. However, there is little research to support this concept- moreover, many studies shows that fasting can have a positive impact on our health.

HYPOTHESIS AND PURPOSE The investigators hypothesize, that the number of meals per day in order to maintain a healthy lifestyle will differ between normal weight, obese, and pre-diabetic subjects.

The investigators will include 1) healthy, normal weight subjects 2) healthy, obese subjects and 3) subjects with pre-diabetes/IGT (impaired glucose tolerance). The investigators will study the effects of two daily meals.

More specifically, the investigators want to better understand how the body reacts to long-term, intermittent fasting (14 h /day for 4 weeks). The investigators will assess cognitive function, dietary intake, appetite regulation, fitness, glucose and insulin responses, as well as fat and muscle composition of the body before, during, and after the study.

Our long-term goals are to compare the effects of intermittent fasting with the three or six meals per day. All of this is in an effort to establish how our eating habits ultimately affect our health and to, perhaps, contribute to new recommendations for healthy eating in normal weight, obese, and pre-diabetic populations.

BACKGROUND Obesity and diabetes are increasing health threats facing the Western world today, despite abundant research efforts and campaigns to prevent such outcomes. Throughout the years, as the incidence of both obesity and diabetes in the general population has increased, so too has the typical number of daily meals. A once common three meals per day has now increased to six meals per day, in many instances. Recent animal research has shown that intermittent fasting (one or two meals per day) over a long period of time can improve cardiovascular health and prevent chronic diseases. Biochemically, fasting leads to an activation of metabolic mechanisms designed to preserve carbohydrates and increase the dependence on energy produced by the metabolism of fat. There is little scientific evidence regarding the number of meals per day that proves to be the healthiest, and those studies that do exist have opposing conclusions. Several theories do exist regarding the number of meals per day that affect us in the most favorable way, but these are just theories. Our study is the first to assess, in both a systematic and controlled setting, how long-term, intermittent fasting affects the human body.


Condition Intervention
Intermittent Fasting
Meal Frequency
Behavioral: Meal frequency from 2 to 6 meals per day

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: VEK-H-3-2011-023. Fasting and Meal Project

Resource links provided by NLM:


Further study details as provided by Rigshospitalet, Denmark:

Primary Outcome Measures:
  • oral glucose tolerance test [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    OGTT with stable isotopes. To see the effect of plasma glucose mmol/L and plasma insulin pmol/L 1 month after intervention (2 months from beginning of the study).


Secondary Outcome Measures:
  • Continuous glucose monitoring (CGM) [ Time Frame: 2 months ] [ Designated as safety issue: No ]
    During the control period and the intervention the CGM system will measure the continuous glucose concentration (each 5 min), and thereby any change will be measured.


Estimated Enrollment: 140
Study Start Date: June 2011
Estimated Study Completion Date: June 2014
Estimated Primary Completion Date: June 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Normal weight
Body Mass Index between 18-25 kg/m2 Age between 18-35 years male/female
Behavioral: Meal frequency from 2 to 6 meals per day

Each of the 140 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.

DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)

  • 28 days of dietary monitoring
  • 28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1
  • Oral glucose tolerance test with stable isotopes
  • Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2
  • DXA scanning
  • Resting Metabolic Rate Measurement
  • VO2max test on bicycle
  • Cognitive testing
  • MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3
  • Actiheart for 3 days
  • 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION
  • Fasting from 7am - 9pm OR 3 OR 6 meals per day
  • 28 days of dietary monitoring
  • 28 days measurement by pedometer
Experimental: Obese
Body Mass Index between 18-25 kg/m2 Age between 18-35 years Male/female
Behavioral: Meal frequency from 2 to 6 meals per day

Each of the 140 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.

DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)

  • 28 days of dietary monitoring
  • 28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1
  • Oral glucose tolerance test with stable isotopes
  • Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2
  • DXA scanning
  • Resting Metabolic Rate Measurement
  • VO2max test on bicycle
  • Cognitive testing
  • MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3
  • Actiheart for 3 days
  • 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION
  • Fasting from 7am - 9pm OR 3 OR 6 meals per day
  • 28 days of dietary monitoring
  • 28 days measurement by pedometer
Experimental: Obese with pre-diabetes (impaired glucose tolerance)
Body Mass Index between 18-25 kg/m2 Age between 18-35 years male/female
Behavioral: Meal frequency from 2 to 6 meals per day

Each of the 140 subjects must through a period of monitoring (four weeks) before the study period (four weeks). Before, during, and after both the monitoring period and the study period, the subjects will undergo tests at Rigshospitalet.

DAY 1: Inclusion and exclusion of subjects DAY 1 to DAY 28: Monitoring period (usual lifestyle)

  • 28 days of dietary monitoring
  • 28 days measurement by pedometer DAY 1, DAY 28 & DAY 56: Test 1
  • Oral glucose tolerance test with stable isotopes
  • Fat and muscle biopsies DAY 2, DAY 29 & DAY 57: Test 2
  • DXA scanning
  • Resting Metabolic Rate Measurement
  • VO2max test on bicycle
  • Cognitive testing
  • MRI of the brain and abdomen DAY 9, DAY 19, DAY 38 & DAY 48: Test 3
  • Actiheart for 3 days
  • 72-hour blood glucose monitoring with CGMS System DAY 29 to DAY 57: INTERVENTION
  • Fasting from 7am - 9pm OR 3 OR 6 meals per day
  • 28 days of dietary monitoring
  • 28 days measurement by pedometer

  Eligibility

Ages Eligible for Study:   18 Years to 35 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Physically active, defined as at least 8,000 steps per day
  • Regular meal frequency, i.e. energy intake=energy utilized, and eating between 3-6 meals per day
  • Regular menses (cycles max 32 days)

Exclusion Criteria:

  • Daily medications
  • Acute illness within the past two weeks (infection, fever, or surgery)
  • Chronic disease, including cancer, heart, liver, kidney, and respiratory diseases, as well as metabolic diseases, such as diabetes
  • Alcohol abuse or more than 14/21 units (women/men) consumed per week
  • Smoking, including occasional smoking
  • Positive pregnancy test
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01378208

Contacts
Contact: Nina M Harder, MD +45 35450898 Nina.Majlund.Harder@rh.regionh.dk

Locations
Denmark
Centre of Inflammation and Metabolism, Rigshospitalet Recruiting
Copenhagen OE, Copenhagen, Denmark, 2100
Contact: Nina M Harder, MD     +45 35450898     Nina.Majlund.Harder@rh.regionh.dk    
Sponsors and Collaborators
Inge Holm
Investigators
Study Director: Bente K Pedersen, Professor Rigshospitalet, Denmark
  More Information

No publications provided

Responsible Party: Inge Holm, CIM Administrator, Rigshospitalet, Denmark
ClinicalTrials.gov Identifier: NCT01378208     History of Changes
Other Study ID Numbers: VEK-H-3-2011-023
Study First Received: June 15, 2011
Last Updated: May 31, 2012
Health Authority: Denmark: The Danish National Committee on Biomedical Research Ethics for the Capital Region
Denmark: Danish Dataprotection Agency

Keywords provided by Rigshospitalet, Denmark:
Intermittent fasting
Meal frequency
obesity
pre-diabetes

ClinicalTrials.gov processed this record on May 22, 2013